This randomised, controlled trial demonstrates that Sativex® was significantly superior to placebo in reducing the mean intensity of pain (p=0.005) and sleep disturbance (p=0.003) amongst people with MS. The study was conducted in 66 patients, 65% of whom required support to walk or were wheelchair bound and were suffering from moderate to severe central neuropathic pain which had not been alleviated by currently available medications. Patients continued to take their existing medication throughout the trial. Sativex® was administered as an oromucosal spray allowing flexible dosing which is ideally suited to the variable nature of MS. Sativex® was generally well tolerated in the study, although more patients on Sativex® than placebo reported dizziness, dry mouth and somnolence. Cognitive side effects were limited to long-term memory storage.
Here's the cite:
D.J.Rog, T.J.Nurmikko, T.Friede, and C.A Young. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812
I wonder if they had problems with "unmasking" in this one...
Link to press release.
technorati tags: multiple sclerosis, medical marijuana